The VEGF Polyclonal Antibody (CAB12303) is a valuable tool for researchers studying vascular endothelial growth factor (VEGF), a key player in angiogenesis and vascular permeability. This antibody, produced in rabbits, exhibits high specificity and sensitivity for human samples and is optimized for use in Western blot applications.VEGF is a crucial signaling protein that promotes the formation of new blood vessels, a process essential for tissue growth and repair. Dysregulation of VEGF expression is associated with various diseases, including cancer, diabetic retinopathy, and cardiovascular disorders. The VEGF Polyclonal Antibody allows for the precise detection and quantification of VEGF levels in different cell types and tissues, enabling detailed analysis in immunology and cancer research studies.
By targeting VEGF, researchers can gain insights into the mechanisms driving angiogenesis and vascular pathologies, leading to the development of novel therapeutic strategies for treating a wide range of conditions. The VEGF Polyclonal Antibody is a reliable tool for investigating the role of VEGF in health and disease, making it an indispensable asset for researchers in the field of vascular biology and oncology.
Product Name:
VEGF Rabbit Polyclonal Antibody
SKU:
CAB12303
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Mouse,Rat
Immunogen:
Recombinant fusion protein containing a sequence corresponding to amino acids 91-191 of human VEGFA (NP_001165097.1).
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines.
Purification Method:
Affinity purification
Gene ID:
7422
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.05% proclin300,50% glycerol,pH7.3.
Western blot analysis of various lysates, using VEGFA Rabbit pAb (CAB12303) at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25μg per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 30s.
